The plan follows the disease, not the calendar
Liver cancer is not one disease. Hepatocellular carcinoma, intrahepatic cholangiocarcinoma and metastatic cancer in the liver behave differently, and the treatment options differ accordingly. A plan is a working proposal based on the information available at a point in time. When that information changes, the proposal should be revisited rather than followed mechanically.
In practice, a plan can change for two broad reasons. The first is new evidence about the cancer: its size, number and location of tumours, whether it has spread, what the pathology shows, and whether biomarkers point to a particular therapy. The second is new evidence about the patient: how well the liver is working, whether there is cirrhosis and how severe it is, kidney and blood results, other illnesses, performance status and the patient's own priorities.
Neither reason is unusual. A plan that never changes may mean the situation is stable, or it may mean the review has not happened. The useful question is not whether the plan will change, but which findings would prompt a change and who reviews them.
New imaging or pathology can restage the cancer
Staging is the foundation of treatment selection. If a scan shows more tumours than before, a larger lesion, invasion of blood vessels or spread outside the liver, the stage may shift and with it the recommended approach. A lesion that looked treatable with local ablation or resection may need a different strategy if it is closer to a major vessel or involves more of the liver.
Pathology matters too. A biopsy or surgical specimen can confirm the tumour type and grade, and molecular testing may identify targets relevant to systemic therapy. Guidance from the American Society of Clinical Oncology and the National Comprehensive Cancer Network treats stage, liver function and performance status as the core inputs to hepatocellular carcinoma decisions, with pathology and molecular information increasingly relevant for other liver cancers and for systemic options.
A patient arriving in China with imaging from another country should expect the receiving team to review the images themselves, not only the written report. Ask whether the hospital will re-read the scans and whether it needs the original image files rather than photographs or PDF summaries.
Liver function and cirrhosis can rule options in or out
Many liver cancer treatments depend on the liver's reserve. Surgery, ablation and embolisation place demands on liver tissue, and systemic therapies can affect liver function. If cirrhosis is advanced or liver function has declined, an option that looked suitable earlier may become unsafe, and a less invasive approach may be preferred.
This is why liver function tests, clotting studies, imaging of the liver's texture and signs of portal hypertension are part of the assessment. A change in these results between visits can change the recommendation even if the tumour looks the same. The treating hepatologist or surgeon makes that judgement; a patient cannot infer it from a single blood result.
Ask the team which liver function measures they use for decision-making, what threshold would make a given option unsuitable, and whether the assessment needs to be repeated before treatment starts.
Response to earlier treatment, or a complication, can redirect care
If a first treatment has been given, the next plan depends on how the cancer responded and how the patient tolerated it. Imaging after treatment may show shrinkage, stability or progression. Progression usually prompts a review of alternatives, while significant side effects may call for dose adjustment, a different agent or a pause.
Complications also change plans. Bleeding, infection, worsening jaundice, ascites or kidney injury can require treatment to be delayed or modified. These are clinical events that the treating team manages; they are not reasons to persist with a schedule that no longer fits the patient's condition.
Patients should ask what follow-up imaging is planned, what result would be considered progression, and what alternatives exist if the current treatment stops working or cannot be tolerated.
What to bring so the review is based on evidence
A treatment review is only as good as the records behind it. For liver cancer, the most useful file usually includes imaging discs or files from the original scanner, not just reports; pathology reports and, where relevant, tissue blocks or slides; blood results including liver and kidney function and tumour markers; a list of previous treatments with dates and outcomes; and a summary of other medical conditions and current medicines.
Records should be translated where the receiving team cannot read the originals. Ask the hospital whether it accepts reports in English or needs a certified translation, and whether it will review records before an appointment. These are practical questions to confirm with the specific provider rather than assumptions about how Chinese hospitals work.
It also helps to write down the patient's main question. A team can address a focused question, such as whether surgery is still possible or whether a systemic option is worth considering, more usefully than a general request for advice.
Questions that make a plan review concrete
When a plan changes, or when a patient wants to understand whether it should, the most useful questions are specific. Which finding triggered the change? What is the new stage and liver function assessment? Which options are now recommended, and which are no longer suitable? What would make the team revisit the plan again? What are the alternatives if the preferred option is unavailable or not tolerated?
It is also reasonable to ask how the recommendation relates to published guidance and to the patient's own goals. Clinicians can discuss evidence-based risk and benefit estimates for an individual without guaranteeing an outcome. A second opinion from another specialist is a normal part of cancer care, and the receiving clinician can comment on the records independently.
For international patients considering care in China, the hospital decides whether it can accept the case and what treatment it can offer. An initial enquiry to ChinaSpecialistCare is free and can clarify which records are missing and what the next practical step might be; it is not a diagnosis or a promise of acceptance. A proxy consultation or multidisciplinary review is optional and can be discussed if a records-based opinion would help before travel.
Sources & scope of this guide
References and official service information relevant to this guide.
- Oncology
- Related treatment reference
- Liver and Bile Duct Cancer—Health Professional Version - NCI
- Liver Diseases | Hepatic Diseases | MedlinePlus
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.
